| abstract |
The present invention relates to human monoclonal antibodies that bind to human mesothelin. The four antibodies (internal names MIOMS-1, MIOMS-2, MIOMS-4 and MIOMS-6) are characterized by their CDR sequences. The antibodies are obtained by a phage exposure technique. According to the invention, ELiSa and FACS binding assays demonstrate specific binding of antibodies to mesothelin antibody conjugates that include mesothelin-specific monoclonal antibodies (or antigen-binding fragments). The invention further provides methods for detecting, diagnosing, and treating mesothelin-positive cancer. |